imatinib mesylate has been researched along with Cytokine Release Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, RR; Cheng, T; Guan, Y; Hu, GS; Hu, YH; Lin, HW; Liu, JY; Liu, W; Ma, J; Qi, RY; Xia, L; Xia, NS; Xiong, HL; Yu, C; Yuan, LZ; Zhang, JM; Zhang, TY; Zheng, ZZ; Zhou, M | 1 |
1 other study(ies) available for imatinib mesylate and Cytokine Release Syndrome
| Article | Year |
|---|---|
A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
Topics: Caspofungin; COVID-19; Cytokine Release Syndrome; Cytokines; Felodipine; Humans; Imatinib Mesylate; Inflammation; Receptors, Chimeric Antigen; SARS-CoV-2 | 2023 |